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Abstract
To investigate the species distribution within the Acinetobacter calcoaceticus–Acinetobacter baumannii complex and the molecular epidemi-
ology of A. baumannii and Acinetobacter nosocomialis, 376 Acinetobacter isolates were collected prospectively from hospitalized patients at
15 medical centres in Germany during three surveillance studies conducted over a 5-year period. Species identification was performed
by molecular methods. Imipenem minimum inhibitory concentrations (MIC) were determined by broth microdilution. The prevalence of
the most common carbapenemase-encoding genes was investigated by oxacillinase (OXA) -multiplex polymerase chain reaction (PCR).
The molecular epidemiology was investigated by repetitive sequence-based PCR (rep-PCR; DiversiLab). Acinetobacter pittii was the
most prevalent Acinetobacter species (n = 193), followed by A. baumannii (n = 140), A. calcoaceticus (n = 10) and A. nosocomialis (n = 8).
The majority of A. baumannii was represented by sporadic isolates (n = 70, 50%) that showed unique rep-PCR patterns, 25 isolates
(18%) clustered with one or two other isolates, and only 45 isolates (32%) belonged to one of the previously described international
clonal lineages. The most prevalent clonal lineage was international clone (IC) 2 (n = 34) and IC 1 (n = 6). According to CLSI, 25 A. bau-
mannii isolates were non-susceptible to imipenem (MIC ‡ 8 mg/L), all of which produced an OXA-58-like or OXA-23-like carbapenem-
ase. The rate of imipenem susceptibility among A. baumannii isolates decreased from 96% in 2005 to 76% in 2009. All other
Acinetobacter isolates were susceptible to imipenem. The population structure of carbapenem-susceptible A. baumannii in Germany is
highly diverse. Imipenem non-susceptibility was strongly associated with the clonal lineages IC 2 and IC 1. These data underscore the
high clonality of carbapenem-resistant A. baumannii isolates.
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Introduction
The genus Acinetobacter is composed of 25 distinct species
with valid species names and a number of as yet unnamed
species including both environmental and clinically relevant
species [1]. Of these, Acinetobacter baumannii and Acineto-
bacter nosocomialis are the most important pathogens causing
mainly nosocomial infections, especially in intensive-care units
(ICUs) [1–3]. Because of their phenotypic and genotypic
similarity, A. baumannii, Acinetobacter pittii (previously Acineto-
bacter genomic species 3), A. nosocomialis (previously Acineto-
bacter gen. sp. 13TU), and A. calcoaceticus were combined
into the A. calcoaceticus–A. baumannii complex (Acb complex)
[1,2]. From a clinical point of view this is problematic
because A. calcoaceticus, in contrast to the other three spe-
cies, is considered an environmental species that has not
been implicated in clinical disease [1,2]. Furthermore, this
similarity makes correct identification to species level difficult
for routine microbiology laboratories [1,2].
Over the last decade the resistance of A. baumannii to the
carbapenems as well as the increasing number of hospital
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outbreaks have become matters of concern [3–5]. Carbape-
nem resistance was first described in A. baumannii in the
early 1990s [1]. It is most often mediated through carbape-
nem hydrolysing enzymes although permeability may also
play a role. The most common carbapenemases in A. bau-
mannii are class D oxacillinases (OXA) which encompass the
intrinsic OXA-51-like, and the acquired OXA-23-like, OXA-
58-like, OXA-40-like and OXA-143 enzymes [6,7]. Overex-
pression of OXA enzymes is often associated with insertion
elements.
To date, studies on the molecular epidemiology of A. bau-
mannii have identified eight worldwide clonal lineages
(WW1–WW8) hereafter referred to as international clones
(IC) 1–8 [8]. IC 1–IC 3 correspond to the European clones
I–III [8]. IC 2 is the most widespread clonal lineage and it is
often associated with carbapenem resistance [8–10].
The aim of this study was to investigate the species distri-
bution among clinical Acinetobacter isolates and the molecular
epidemiology of carbapenem-susceptible and non-susceptible
A. baumannii and A. nosocomialis isolates recovered in Ger-
many over a 5-year period (2005–2009).
Materials and Methods
Bacterial strains
In all, 388 Acinetobacter isolates were collected as part of the
German Tigecycline Evaluation Surveillance Study (G-TEST)
[11]. Fifteen microbiological diagnostic laboratories, most of
them from large referral medical centres, provided prospec-
tively collected clinical isolates from hospitalized patients
with community-acquired or nosocomial infections during
three study periods in 2005, 2007 and 2009. Each collecting
centre was requested to provide ten A. baumannii isolates
from different patients per study period.
Species identification
Species identification was initially performed using semi-auto-
mated identification systems at the different participating
centres. Identification at the species level of isolates of the
Acb complex was performed by gyrB multiplex PCR [12,13].
For isolates not belonging to the Acb complex, ARDRA and
rpoB-sequencing were performed [14,15].
Molecular typing
The molecular epidemiology of A. baumannii and A. nosocomi-
alis isolates was investigated using the DiversiLab system
(bioMe´rieux, Nu¨rtingen, Germany) [16]. Results were analy-
sed with the DIVERSILAB software using the Kullback–Leibler
statistical method and a cluster was defined as at least two
isolates with a similarity index ‡95% [8]. Isolates having a
similarity index of ‡99% were considered identical [17]. In
addition, A. baumannii isolates were investigated by the
sequence-type multiplex PCR as described by Turton et al.
[4].
Antimicrobial susceptibility testing and detection of
carbapenemase genes
Imipenem MICs were determined by broth microdilution
according to the standard of the German DIN (Deutsches
Institut fu¨r Normung) 58940 guidelines [11,18]. For the pur-
pose of this study, CLSI breakpoints were used to interpret
imipenem MICs [19]. Isolates with an imipenem MIC ‡8 mg/
L were considered non-susceptible to imipenem. OXA-multi-
plex PCR was used to detect Acinetobacter carbapenemase-
encoding genes as previously described [20,21].
Results
Species identification
The species distribution of isolates is summarized in Tables 1
and 2. Among 388 isolates submitted as A. baumannii by the
collecting centres, 11 isolates were found not to belong to
the genus Acinetobacter and one could not unambiguously be
identified to species level. These isolates were excluded from
further analysis. Among the remaining 376 Acinetobacter iso-
lates, the most prevalent species was A. pittii (n = 193; 51%);
A. baumannii accounted for 140 isolates (37%); ten isolates
were A. calcoaceticus (3%); eight isolates were A. nosocomialis
(2%); and 25 isolates were other Acinetobacter spp. (7%). Iso-
TABLE 1. Species distribution of Acinetobacter isolates
(n = 376) from the German Tigecycline Evaluation Study
(G-TEST) by study period
Species
No. of isolates in each
study period
Total2005 2007 2009
A. pittii 73 49 71 193
A. baumannii 46 52 42 140
A. calcoaceticus 3 2 5 10
A. nosocomialis 5 1 2 8
A. lwoffii 1 4 1 6
A. bereziniae 1 4 5
A. haemolyticus 1 2 3
A. ursingii 2 1 3
Acinetobacter close to 13TU 1 1
A. gyllenbergii 1 1
A. beijerinckii 1 1
A. johnsonii 1 1
A. radioresistens 1 1
A. junii 1 1
Acinetobacter gen. sp. 13BJ 1 1
Acinetobacter gen. sp. 14BJ 1 1
Total 133 114 129 376
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lates were recovered from respiratory tract specimens
(34%), wound swabs (29%), blood cultures (21%) and intra-
abdominal specimens (8%). Of these isolates, 68% were from
patients cared for on general wards and 32% were from ICU
patients.
Although A. baumannii (48%) was the most prevalent Aci-
netobacter species recovered from ICU patients followed by
A. pittii (44%), A. pittii was the predominant species obtained
from patients in general wards (56%) whereas A. baumannii
accounted for only 31% of those isolates (p < 0.005;
Table 2). Of ten A. calcoaceticus isolates, five were obtained
from the respiratory tract, four from wound swabs and one
from urine from patients on general wards (internal medicine
(three isolates), surgery (two isolates), haematology/oncology
(two isolates), dermatology, orthopaedics and paediatrics,
one isolate each) from seven different centres. Their true
clinical significance, however, remains uncertain.
Molecular typing
The results of the repetitive sequence-based PCR (rep-PCR)
analysis of 140 A. baumannii isolates, along with the number
of centres where these isolates were recovered are shown
in Table 3. Seventy A. baumannii isolates were considered
sporadic isolates showing unique rep-PCR patterns. Twenty-
five isolates clustered with one or two other strains and rep-
resented ten small clusters that did not correspond to the
major international clonal lineages. Whereas four of the
small clusters contained similar but not identical isolates,
three of the small clusters consisted of two identical isolates
each. Isolates from these clusters were obtained from the
same centre and study period and therefore probably repre-
sented transmission from patient to patient. The remaining
three small clusters included both similar and identical
strains. Among these, two identical isolates obtained from
one centre but in different years may indicate persistence or
reintroduction of this strain.
Forty-five A. baumannii isolates (32%) clustered with one
of the previously described international clonal lineages
IC 1–8. The most prevalent clonal lineage was IC 2 (34 of
140 isolates; 24.3%). The high prevalence in 2007 was most
probably a result of hospital outbreaks that occurred at five
centres comprising up to five isolates. The IC 2 isolates were
geographically widespread; strains were obtained from 12 dif-
ferent centres, i.e. from six centres in 2005 and 2007 and
from seven centres in 2009. In addition, we identified six
IC 1 isolates, four IC 4 isolates and one IC 7 isolate. In
2009, five IC 1 isolates were obtained from one centre
within 3 weeks. Four of these isolates were identical as
determined by rep-PCR.
For comparison, sequence-type multiplex PCR was per-
formed for all A. baumannii isolates. Only two of 6 IC 1
(33.3%) isolates and 22 of 34 IC 2 isolates (64.7%) showed
the expected electrophoresis pattern, indicating that this
method although being a convenient first approach to molec-
TABLE 2. Species distribution of
Acinetobacter isolates on intensive-
care unit (ICU; n = 124) and non-
ICU (n = 242) wards*
Ward
Species
A. baumannii A. pittii A. nosocomialis A. calcoaceticus
Other
Acinetobacter spp.
No. (percent) of isolates
ICU 59 (48) 54 (44) 3 (2) 8 (6)
Non-ICU 74 (31) 136 (56) 5 (2) 10 (4) 17 (7)
*No data are available on the origin for 10 Acinetobacter isolates and are excluded from this table.
TABLE 3. Molecular epidemiology of Acinetobacter baumannii as determined by repetitive sequence-based polymerase chain
reaction
Molecular typing
results
Year of isolation
2005 2007 2009
No. of isolates (no. of centres) and percentage of isolates representing clustered and unclustered isolates
Unclustered 28 (14) 61% 23 (12) 44% 19 (12) 45%
Part of a small cluster 9 (4) 20% 10 (4) 19% 6 (6) 14%
IC 2 6 (6) 13% 18 (6) 35% 10 (7) 24%
IC 1 1 (1) 2% 5 (1) 12%
IC 4 2 (1) 4% 1 (1) 2% 1 (1) 2%
IC 7 1 (1) 2%
Total 46 52 42
IC, international clone.
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ular typing of A. baumannii in the outbreak setting needs to
be complemented by other typing methods to reliably iden-
tify the major clonal lineages if A. baumannii isolates repre-
senting a more diverse epidemiological background are to be
investigated.
The rep-PCR analysis of A. nosocomialis showed that six of
eight isolates had unique banding patterns. Two isolates
recovered in 2005 from one centre had similar (98.6%) but
not identical banding patterns.
Antimicrobial susceptibility testing
Over the 5-year period, carbapenem non-susceptible A. bau-
mannii increased from 4.3% in 2005, to 25% and 23.8% in
2007 and 2009, respectively. The proportion of isolates that
were non-susceptible to imipenem was higher among isolates
belonging to IC 2 and IC 1 than among other A. baumannii
isolates. Among IC 2 (n = 34) and IC 1 (n = 6) isolates, 22
(55%) were non-susceptible to imipenem, whereas only three
(3%) of the remaining A. baumannii isolates were non-suscep-
tible to imipenem. All Acinetobacter isolates other than A. bau-
mannii were susceptible to imipenem including isolates that
harboured an acquired blaOXA gene (Table 4). Susceptibility
data of other antimicrobial compounds have been published
previously [11].
Prevalence of blaOXA genes
Table 4 summarizes the presence of acquired blaOXA
genes in Acinetobacter species. All imipenem-non-susceptible
A. baumannii were found to harbour blaOXA genes. In 2005,
the only acquired blaOXA gene found in A. baumannii was
blaOXA-58-like (n = 2). In 2007, four isolates harbouring
blaOXA-23-like genes and nine isolates harbouring blaOXA-58-like
genes were detected. Whereas the number of blaOXA-23-like
genes increased in 2009 (n = 10), strains harbouring OXA-
58-like were no longer found. Acquired blaOXA genes were
also detected in 12 imipenem-susceptible Acinetobacter iso-
lates other than A. baumannii, including seven A. pittii isolates.
Discussion
This is the first study providing representative data on the
molecular epidemiology of A. baumannii in Germany, as it
includes isolates collected prospectively during comparable
time periods in 2005, 2007 and 2009 from different German
medical centres.
The distribution of Acinetobacter species in countries other
than Germany has been investigated in several studies showing
very different results. In this study, A. pittii (51%) and A. bau-
mannii (37%) were the two predominant Acinetobacter species.
Acinetobacter pittii was also the most prevalent species among
114 Acinetobacter isolates recovered in an Irish hospital [22].
In contrast, A. nosocomialis (46.9%) was the most frequent spe-
cies followed by A. pittii (19.5%) in a recent study of Acineto-
bacter bloodstream isolates from Norway [23]. In another
study from the UK, A. baumannii (78%) was followed in fre-
quency by Acinetobacter lwoffii (8.8%) and Acinetobacter ursingii
(4%), whereas A. pittii made up only 1.7% of Acinetobacter iso-
lates [24]. Wisplinghoff et al. [25] investigated 295 Acinetobac-
ter isolates from patients with bloodstream infections from
the USA. Of these isolates, 63% were identified as A. bauman-
nii, 21% as A. nosocomialis and 8% as A. pittii. Of interest, clinical
outcome was less favourable in patients with bloodstream
infections caused by A. baumannii [25]. Chuang et al. [26] pre-
sented similar results from Taiwan, showing a predominance
of A. baumannii in bacteraemia cases that were associated with
a higher mortality and resistance to antibiotics.
Our results confirm previous work indicating the impor-
tance of using genetic methods for identification of Acineto-
bacter spp. [2]. In this study, of 376 Acinetobacter isolates
identified as A. baumannii by the collecting centres, further
testing revealed that 351 (90%) belonged to the Acb com-
plex, of which 140 isolates were confirmed as A. baumannii
and 193 isolates were A. pittii. This finding underscores the
fact that the phenotypic identification methods based on
semi-automated identification systems that are usually
employed in large international surveillance studies are insuf-
ficient and may largely overestimate the prevalence of A. bau-
mannii while underestimating the prevalence of other
TABLE 4. Prevalence of acquired blaOXA genes in Acineto-
bacter spp. by study period. For A. baumannii, data of molec-
ular typing by repetitive sequence-based polymerase chain
reaction is included
Species
Year of isolation
2005 2007 2009
blaOXA-like genes detected (no. of isolates)
A. baumannii
(n = 25)
Unclustered OXA-58 (n = 2)
IC 1 OXA-23 (n = 4)
IC 2 OXA-58 (n = 8) OXA-23 (n = 6)
OXA-23 (n = 4)
IC 4 OXA-58 (n = 1)
A. pittii (n = 7) OXA-23 (n = 1) OXA-23 (n = 1) OXA-23 (n = 1)
OXA-58 (n = 1) OXA-58 (n = 3)
A. calcoaceticus OXA-40 (n = 1)
Acinetobacter
gen. sp. 13BJ
OXA-23 (n = 1)
Acinetobacter gen.
sp. 14BJ
OXA-58 (n = 1)
A. radioresistens* OXA-23 (n = 1)
A. junii OXA-58 (n = 1)
IC, international clone.
*OXA-23 is intrinsic to A. radioresistens
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Acinetobacter species and their potential clinical relevance.
Furthermore, these data suggest that carbapenem resistance
in A. baumannii may have been underestimated in previous
studies by inclusion of Acinetobacter isolates potentially mis-
identified as A. baumannii [26–28].
It may be speculated that multi-drug resistance and in par-
ticular carbapenem-resistance of A. baumannii could explain
its success in the ICU environment where exposure to anti-
biotics is high and where other, more susceptible Acinetobac-
ter species may not survive [2]. In fact, in our study 25% of
A. baumannii isolates recovered from ICU patients were non-
susceptible to imipenem whereas this was true for only 12%
of isolates from general ward patients. On general wards
where there is less antibiotic selection pressure, A. pittii
might predominate over A. baumannii, in part because A. pittii
is part of the human skin flora and can be introduced from
the community [29]. Similarly, the prevalence of methicillin-
resistant Staphylococcus aureus on ICUs is usually higher than
on general wards [30].
The molecular epidemiology of A. baumannii in Germany
confirms the previously described predominance of IC 2
among clinical A. baumannii isolates and the association
between epidemic clonal lineages, in particular of IC 2, and
non-susceptibility to carbapenems [9,10]. The majority of
A. baumannii isolates, however, were sporadic isolates with
unique rep-PCR patterns and isolates representing small clus-
ters. Over the 5-year-period the percentage of isolates repre-
senting IC 1 and IC 2 increased from 15.2% to 35.7%, and of
the 25 imipenem non-susceptible A. baumannii isolates, 18 iso-
lates were IC 2 and four were IC 1. In addition, one IC 4 iso-
late and two sporadic isolates were non-susceptible to
imipenem. All isolates had either OXA-58-like or OXA-23-
like carbapenemases. Of note, we observed a small outbreak
involving four identical isolates belonging to IC 1 at one cen-
tre in 2009, the isolates were non-susceptible to imipenem
and harboured a blaOXA-23-like gene. The predominance of
IC 1 and IC 2 among carbapenem-resistant A. baumannii iso-
lates has been shown previously [9,10]. Importantly, an excel-
lent correlation of rep-PCR and multilocus sequence typing
to identify the major international clonal lineages was recently
shown among A. baumannii bloodstream isolates [31].
The prevalence of blaOXA genes among A. baumannii chan-
ged over the 5-year period with a decrease of isolates har-
bouring blaOXA-58-like and an increase in isolates harbouring
blaOXA-23-like genes. Our data support previous findings from
the USA and worldwide indicating OXA-23 being the most
frequent acquired carbapenemase found in A. baumannii
[9,32]. The increasing prevalence of blaOXA-23-like genes is
probably the result of the increasingly widespread presence
of AbaR4 islands, which contain it [33].
Our study has several limitations. First, mainly isolates
that were identified by semi-automated systems as A. bau-
mannii or Acb complex were included, and isolates not
belonging to the Acb complex are therefore underrepre-
sented. Second, although A. pittii was the most prevalent
species among our isolates, these isolates were not sub-
jected to molecular typing. However, high heterogeneity
among A. pittii bloodstream isolates was shown previously
by plasmid profiling [34], and it was therefore considered
unnecessary to repeat these analyses. Third, the sampling
strategy employed (i.e. ten isolates per centre and year) and
the epidemiological patient data available do not allow
assessment of the role of nosocomial cross-transmission.
Also, the impact of Acinetobacter hospital outbreaks in Ger-
many, although they appear to be infrequent, could not be
reliably explored.
In conclusion, this nationwide study showed a high preva-
lence of A. pittii both among patients hospitalized on general
wards and in patients in the ICU. Our data also confirm that
carbapenem resistance is mainly found in A. baumannii and
may contribute to its increasing clonal spread, most notably
that of IC 2. More accurate identification of Acinetobacter
species in routine microbiology laboratories might clarify the
true clinical impact and expansion of carbapenem-resistant
A. baumannii clonal lineages in relation to other A. baumannii
strains. Of note, we identified common blaOXA genes in Aci-
netobacter spp. other than A. baumannii, though these isolates
were still susceptible to imipenem. Our data suggest that
currently carbapenem-resistant Acinetobacter in Germany
mainly involves A. baumannii. However, as carbapenem resis-
tance has been described in other Acinetobacter species
including A. nosocomialis and A. pittii [35,36], it is important to
monitor carbapenem-resistance and the prevalence of resis-
tance genes in these species.
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